Abstract:Simple Summary The formats of bispecific antibody have been investigated for many years to enhance the stability of the structure and anti-tumor efficacy. One of the formats combining two Fabs at their C termini provides unmodified variable region and comparable activity to other fragment-based bispecific antibodies that are usually combined in a head-to-tail manner. However, the current strategy to produce the BiFab molecule is limited to a semisynthetic method that introduces unnatural amino acid to antibodies' sequences during production. To improve the application of BiFab format in investigational biodrugs, we have applied sortase A-mediated "bio-click" chemistry to generate BiFab, for facile assembly of Fab molecules that have been expressed and stored as BiFab module candidates. The BiFabs made by our method stimulate T cell proliferation and activation with favorable in vitro and in vivo anti-tumor activit. Our results indicate that BiFab made by sortase A-mediated click chemistry could be used to efficiently generate various BiFabs with high potency, which further supports personalized tumor immunotherapy in the future. Bispecific antibodies (BsAbs) for T cell engagement have shown great promise in cancer immunotherapy, and their clinical applications have been proven in treating hematological malignance. Bispecific antibody binding fragment (BiFab) represents a promising platform for generating non-Fc bispecific antibodies. However, the generation of BiFab is still challenging, especially by means of chemical conjugation. More conjugation strategies, e.g., enzymatic conjugation and modular BiFab preparation, are needed to improve the robustness and flexibility of BiFab preparation. We successfully used chemo-enzymatic conjugation approach to generate bispecific antibody (i.e., BiFab) with Fabs from full-length antibodies. Paired click handles (e.g., N-3 and DBCO) was introduced to the C-terminal LPETG tag of Fabs via sortase A mediated transpeptidation, followed by site-specific conjugation between two click handle-modified Fabs for BiFab generation. Both BiFab(CD20/CD3) (EC50 = 0.26 ng/mL) and BiFab(Her2/CD3) exhibited superior efficacy in mediating T cells, from either PBMC or ATC, to kill target tumor cell lines while spared antigen-negative tumor cells in vitro. The BiFab(CD20/CD3) also efficiently inhibited CD20-positive tumor growth in mouse xenograft model. We have established a facile sortase A-mediated click handle installation to generate homogeneous and functional BiFabs. The exemplary BiFabs against different targets showed superior efficacy in redirecting and activating T cells to specifically kill target tumor cells, demonstrating the robustness of sortase A-mediated "bio-click" chemistry in generating various potent BiFabs. This approach also holds promise for further efficient construction of a Fab derivative library for personalized tumor immunotherapy in the future.

DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Bispecific FpFs: a versatile tool for preclinical antibody development

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy

An engineered ultra‐high affinity Fab‐Protein G pair enables a modular antibody platform with multifunctional capability

High Antitumor Activity of Sortase A-generated Anti-Cd20 Antibody Fragment Drug Conjugates

Structural basis of a novel heterodimeric Fc for bispecific antibody production

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer

An Antibody Fragment Functionalized Dendritic PEGylated Poly(2-(Dimethylamino)ethyl Diacrylate) As a Vehicle of Exogenous Microrna.

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function

Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

Engineered Protein-G variants for plug-and-play applications

Engineering Bifunctional Antibodies With Constant Region Fusion Architectures

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies

Expression of Multispecific Antibodies